2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.
In addition to the approved PD-1 agents, PD-L1 agents will soon be used in the recurrent metastatic setting, says Weiss. Data with combinations of CTLA-4 agents such as ipilimumab (Yervoy) and nivolumab (Opdivo) or durvalumab (Imfinzi) and tremelimumab will be reported in the coming months, as well.
The combination of PD-1 and IDO inhibitors is also showing promise, Weiss says.
Related Content: